Form 8-K - Current report:
SEC Accession No. 0001104659-23-002047
Filing Date
2023-01-09
Accepted
2023-01-09 07:07:33
Documents
12
Period of Report
2023-01-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm232664d1_8k.htm   iXBRL 8-K 62072
  Complete submission text file 0001104659-23-002047.txt   246696

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vygr-20230108.xsd EX-101.SCH 3066
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vygr-20230108_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vygr-20230108_pre.xml EX-101.PRE 22617
6 EXTRACTED XBRL INSTANCE DOCUMENT tm232664d1_8k_htm.xml XML 3507
Mailing Address 64 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 64 SIDNEY STREET CAMBRIDGE MA 02139 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37625 | Film No.: 23516531
SIC: 2836 Biological Products, (No Diagnostic Substances)